Table 3.

The main toxicity of neoadjuvant EGFR-TKI therapy.

	subcutaneous tissue disorders				Hematologic	Gastrointestinal	Hepatorenal
	Rash		Paronychia	Stomatitis	Leukopenia	Diarrhea	Abnormal liver function
	All grade	≥3 grade	All grade	All grade	≥3 grade	All grade	All grade	≥3 grade
Studies*	4	4	2	1	1	4	4	4
Patients*	103	103	72	37	19	103	103	103
Events	65	2	3	4	1	26	2	1
pooled incidence rates (%)	54.9	14.7	3.8	10.8	5.3	14.7	7.7	5.3
Range (%)	30.3–79.6	2.7–26.8	0–8.2	NA	NA	2.7–26.8	0–16.6	NA

^*Number of studies reporting this toxicity and number of patients included in these studies. NA, Not Applicable.